Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Colorectal Neoplasms 62Carcinoma, Hepatocellular 25Neoplasm Metastasis 15Rectal Neoplasms 11Colonic Neoplasms 10Gastrointestinal Stromal Tumors 9Sarcoma 6Ovarian Neoplasms 5Osteosarcoma 5Glioblastoma 5Cholangiocarcinoma 5Stomach Neoplasms 4Melanoma 4Liver Neoplasms 4Sarcoma, Ewing 3Pancreatic Neoplasms 3Neoplasms 3Leukemia, Myeloid, Acute 3Esophageal Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Rhabdomyosarcoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2Hemangiosarcoma 2Gastrointestinal Neoplasms 2

Interventions

Everolimus 3Temozolomide 2Leucovorin 2Fluorouracil 2Bevacizumab 2vatalanib 1temsirolimus 1regorafenib 1pentetreotide 1pazopanib 1folfirinox 1Vinorelbine 1Thalidomide 1Sirolimus 1Oxaliplatin 1Octreotide 1Irinotecan 1High-Energy Shock Waves 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Doxorubicin 1Cytokines 1Capecitabine 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Islet Cell × regorafenib × Clear all
NCT02259725 2021-12-15

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

University of Southern California

Phase 2 Completed
3 enrolled 7 charts
Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡